Abstract
Interstitial lung abnormalities (ILA) share many features with idiopathic pulmonary fibrosis (IPF), however it is not known if ILA are associated with decreased mean telomere length (MTL).
Telomere length was measured with quantitative polymerase chain reaction in COPDGene and AGES-Reykjavik, and southern blot analysis was used in the Framingham Heart Study (FHS). Logistic and linear regression were used to assess the association between ILA and MTL; Cox proportional hazards models were used to assess the association between MTL and mortality.
In all three cohorts ILA were associated with decreased MTL. In COPDGene and AGES-Reykjavik, after adjustment there was greater than two-fold increase in the odds of ILA when comparing the shortest quartile of telomere length to the longest quartile (odds ratio [OR]=2.2, 95% confidence interval [CI] 1.5–3.4, p=0.0001 and OR=2.6, 95% CI 1.4–4.9, p=0.003), respectively. In the FHS, those with ILA had shorter telomeres compared to those without ILA (−767 bp, 95% CI 76–1584 bp, p=0.03). Although decreased MTL was associated with chronic obstructive pulmonary disease (OR=1.3, 95% confidence interval [CI] 1.1–1.6, p=0.01) in COPDGene the effect estimate was less than that noted with ILA. There was no consistent association between MTL and risk of death, when comparing the shortest quartile of telomere length (hazard ratio [HR]=0.82, 95% CI 0.4–1.7, p=0.6 and HR=1.2, 95% CI 0.6–2.2, p=0.5) in COPDGene and AGES-Reykjavik respectively.
ILA are associated with decreased mean telomere length when compared to those without ILA.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Putman reports grants from NIH/NHLBI, during the conduct of the study;.
Conflict of interest: Dr. Axelsson has nothing to disclose.
Conflict of interest: Dr. Ash reports grants from NHLBI, grants from Pulmonary Fibrosis Foundation, during the conduct of the study; other from Quantitative Imaging Solutions, outside the submitted work;.
Conflict of interest: Dr. Sanders has nothing to disclose.
Conflict of interest: Dr. Menon has nothing to disclose.
Conflict of interest: Dr. Araki has nothing to disclose.
Conflict of interest: Dr. Nishino reports personal fees from Daiichi Sankyo, personal fees from AstraZeneca, grants from Merck investigator studies program, grants from Canon Medical Systems, grants from AstraZeneca, grants from Daiichi Sankyo, outside the submitted work;.
Conflict of interest: Dr. Yanagawa reports non-financial support from Canon Medical Systems, outside the submitted work;.
Conflict of interest: Dr. Gudmundsson has nothing to disclose.
Conflict of interest: Dr. Qiao has nothing to disclose.
Conflict of interest: Dr. San-Jose Estepar reports grants from Boehringer Ingelheim, grants from Lung Biotechnology, grants from Insmed, other from Chiesi, other from Quantitative Imaging Solutions, outside the submitted work;.
Conflict of interest: Dr. Dupuis reports grants from National Institute of Health, during the conduct of the study;.
Conflict of interest: Dr. O'Connor reports grants from NIH, during the conduct of the study;.
Conflict of interest: Dr. Rosas reports In addition, Dr. Rosas has a patent 62/849,644 pending.
Conflict of interest: Dr. Washko reports grants from Boehringer Ingelheim, other from Pulmonx, other from Janssen Pharmaceuticals, other from Novartis, other from Vertex, other from Quantitative Imaging Solutions, outside the submitted work;.
Conflict of interest: Dr. El-Chemaly has nothing to disclose.
Conflict of interest: Dr. Raby reports grants from NIH, outside the submitted work;.
Conflict of interest: Dr. Gudnason has nothing to disclose.
Conflict of interest: Dr. DeMeo reports grants from Novartis, grants from Bayer, during the conduct of the study;.
Conflict of interest: Dr. Silverman reports grants from GlaxoSmithKline, grants from Bayer, during the conduct of the study;.
Conflict of interest: Dr. Hatabu reports grants from Canon Medical Systems inc, grants from Konica-Minolta Inc, personal fees from Mitsubishi Chemical Inc, personal fees from Canon Medical Systems inc, outside the submitted work;.
Conflict of interest: Dr. DeVivo has nothing to disclose.
Conflict of interest: Dr. Cho reports grants from GlaxoSmithKline, grants from Bayer, other from Genentech, other from AstraZeneca, other from Illumina, outside the submitted work;.
Conflict of interest: Dr. Gudmundsson has nothing to disclose.
Conflict of interest: Dr. Hunninghake reports personal fees from Gerson Lehrman Group, personal fees from Boehringer-Ingelheim, outside the submitted work;.
- Received June 27, 2021.
- Accepted December 29, 2021.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
